Loading
institutionsInstitution
Lille University Hospital (CHU de Lille)
The university hospital of Lille, whose blood diseases department under Thierry Facon led MAIA, the trial that made daratumumab-based treatment the standard for older people with myeloma.
Also called: CHU LilleHôpital Claude HuriezService des Maladies du Sang
Overview
The CHU de Lille is one of France's largest university hospitals. Its Service des Maladies du Sang, led for many years by Thierry Facon, is a founding centre of the Intergroupe Francophone du Myélome and led MAIA, the 2019 New England Journal of Medicine trial in which daratumumab plus lenalidomide and dexamethasone lengthened survival in newly diagnosed myeloma patients not eligible for transplant. The Centre Oscar Lambret, Lille's dedicated cancer centre, is a separate institution next door.
Location
Lille, FR
Type
hospital · Université de Lille
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#610 · 4 points (0 Newsweek + 0 NCI + 4 from 2 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Hôpital Claude Huriez, including child institutions. 114 works · 885 citations · 70% open access · 16% clinical trials · 2% reviews.
Oncology works per year
162022
272023
322024
272025
122026
Most works
- Franck Morschhauser23 works
- Laurent Mortier21 works
- Guillaume Piessen15 works
- Emmanuel Bachy13 works
- Guillaume Cartron12 works
- Michael John Dickinson12 works
- Carmelo Carlo‐Stella11 works
- Stéphanie Truant11 works
- Linda Lundberg11 works
- Célèste Lebbé10 works
Most cited
- Multiple myeloma (IFM)
- Haematology
- Transplantation
Similar pages
- TrialMAIA
Shares Thierry Facon, Multiple myeloma.
- TrialIMROZ
Shares Thierry Facon, Multiple myeloma.
- Key paperMAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant
Shares Thierry Facon, Multiple myeloma.
- TargetCD38
Shares Thierry Facon, Multiple myeloma.